Pc4 PDT for Psoriasis
Pc4 PDT 治疗银屑病
基本信息
- 批准号:8319617
- 负责人:
- 金额:$ 21.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-01 至 2013-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAutoimmune DiseasesBlood VesselsCardiovascular DiseasesCardiovascular systemChronicDendritic CellsDiabetes MellitusDiseaseEnvironmentEpidermisEventFunctional disorderFutureHigh Density LipoproteinsHyperlipidemiaHypertensionImmuneImmune systemInflammationInflammatoryInterleukin-2LinkLong-Term EffectsLymphocyteMacrophage ActivationMeasuresMedialMediatingMyelogenousMyeloid CellsMyocardial InfarctionNational Institute of Arthritis and Musculoskeletal and Skin DiseasesPatientsPeroxidasesPopulationProteinsPsoriasisReactionRecruitment ActivityReportingRetrospective StudiesRoleS100A8 geneSerumSerum MarkersSeveritiesSkinSystemic TherapyT-LymphocyteThickTissuesTranslational ResearchUnited StatesVascular Endothelial Growth Factorsaryldialkylphosphatasecardiovascular risk factorcytokineinflammatory markerkeratinocytemacrophageobesity riskprotein expression
项目摘要
Psoriasis is a common chronic immune mediated disease affecting -2% of the US population and is
characterized by an activated immune system. Recent retrospective studies have demonstrated that patients
with psoriasis have an increased risk of obesity, diabetes, hypertension, hyperlipidemia and myocardial
infarction. We hypothesize that the increased cardiovascular risk that occurs in psoriasis may be driven by
the skin inflammation that occurs in psoriasis. S100A8/A9 is synthesized by activated myeloid cells, recruits
them to inflammatory environments, and can serve as a predictor of future cardiovascular events.
S100A8/A9 is significantly upregulated in psoriatic skin in the epidermis and in myeloid cells and levels of
S100A8/A9 in psoriatic tissue and serum correlate with severity of psoriasis. VEGF, another pro-
inflammatory marker is also upregulated in both psoriasis and in cardiovascular disease and can also elicit
macrophage reactions, and appears to regulate S100A8/A9 expression. Following aggressive treatment of
psoriasis, VEGF and S100A8/A9 protein expression are significantly reduced. We propose that skin driven
inflammation generated by elevated levels of proinflammatory S100A8/A9 and VEGF contribute to the
increased cardiovascular risk seen in psoriasis and that aggressive systemic treatment of psoriasis with
potent agents can drive down the cardiovascular risk by decreasing the levels of S100A8/A9 and VEGF. We
will determine: the propensity of patients with psoriasis to develop cardiovascular disease; the effect of short
term treatment of psoriasis with systemic therapies on vascular dysfunction as an indicator of cardiovascular
risk; and the effect of long term treatment of psoriasis with aggressive systemic therapies aimed to maximize
psoriasis control on carotid intimal medial thickness as an indicator of cardiovascular risk. In addition, serum
levels of S100A8/A9 and VEGF as well as other potential serum markers of inflammation, including hsCRP,
myeloperoxidase, dysfunctional HDL and paraoxonase will be measured. Tissues macrophages will be
genomically profiled in an effort to correlate macrophage activation with psoriasis and cardiovascular risk.
Our findings may identify the first direct link between psoriasis, inflammation and cardiovascular risk.
牛皮癣是一种常见的慢性免疫介导疾病,影响 -2% 的美国人口,并且
其特征是免疫系统被激活。最近的回顾性研究表明,患者
患有牛皮癣的人患肥胖、糖尿病、高血压、高脂血症和心肌梗塞的风险增加
梗塞。我们假设银屑病导致的心血管风险增加可能是由于
牛皮癣发生的皮肤炎症。 S100A8/A9由活化的骨髓细胞合成,招募
它们可以将它们引入炎症环境,并可以作为未来心血管事件的预测因子。
S100A8/A9 在银屑病皮肤的表皮和骨髓细胞中显着上调,并且
银屑病组织和血清中的 S100A8/A9 与银屑病的严重程度相关。 VEGF,另一种亲
炎症标志物在牛皮癣和心血管疾病中也会上调,并且还可以引起
巨噬细胞反应,似乎调节 S100A8/A9 表达。积极治疗后
银屑病时,VEGF和S100A8/A9蛋白表达显着降低。我们建议皮肤驱动
促炎性 S100A8/A9 和 VEGF 水平升高产生的炎症有助于
银屑病心血管风险增加,积极全身治疗银屑病
有效的药物可以通过降低 S100A8/A9 和 VEGF 的水平来降低心血管风险。我们
将确定: 牛皮癣患者患心血管疾病的倾向;短的效果
通过以血管功能障碍为心血管指标的全身疗法来治疗牛皮癣
风险;以及采用积极的全身疗法长期治疗牛皮癣的效果,旨在最大限度地发挥作用
银屑病控制颈动脉内膜中层厚度作为心血管风险的指标。此外,血清
S100A8/A9 和 VEGF 的水平以及其他潜在的炎症血清标志物(包括 hsCRP)
将测量髓过氧化物酶、功能失调的高密度脂蛋白和对氧磷酶。组织巨噬细胞将
对巨噬细胞激活与牛皮癣和心血管风险进行基因组分析。
我们的研究结果可能首次确定了牛皮癣、炎症和心血管风险之间的直接联系。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ELMA D BARON其他文献
ELMA D BARON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ELMA D BARON', 18)}}的其他基金
Phase 1 Study of Pc 4 Photodynamic Therapy for Tx of Cutaneous T-Cell Lymphoma
Pc 4 光动力疗法治疗皮肤 T 细胞淋巴瘤 Tx 的一期研究
- 批准号:
8355580 - 财政年份:2012
- 资助金额:
$ 21.58万 - 项目类别:
Phase 1 Study of Pc 4 Photodynamic Therapy for Tx of Cutaneous T-Cell Lymphoma
Pc 4 光动力疗法治疗皮肤 T 细胞淋巴瘤 Tx 的一期研究
- 批准号:
8724218 - 财政年份:2012
- 资助金额:
$ 21.58万 - 项目类别:
Phase 1 Study of Pc 4 Photodynamic Therapy for Tx of Cutaneous T-Cell Lymphoma
Pc 4 光动力疗法治疗皮肤 T 细胞淋巴瘤 Tx 的一期研究
- 批准号:
8544193 - 财政年份:2012
- 资助金额:
$ 21.58万 - 项目类别:
Characterization of Cell Killing after Photodynamic Therapy with Pc4
Pc4 光动力治疗后细胞杀伤的表征
- 批准号:
7502416 - 财政年份:2007
- 资助金额:
$ 21.58万 - 项目类别:
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
相似海外基金
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
- 批准号:
23H02155 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
- 批准号:
10788032 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
- 批准号:
23K14742 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
- 批准号:
10864719 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
- 批准号:
10586562 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
- 批准号:
10593224 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
- 批准号:
23K06589 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
- 批准号:
10623380 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
- 批准号:
10735148 - 财政年份:2023
- 资助金额:
$ 21.58万 - 项目类别:














{{item.name}}会员




